UTEK Corporation and Bacterin International, Inc. Announce Strategic Alliance.

TAMPA, Fla. & BELGRADE, Mont. -- UTEK Corporation (AMEX:UTK) (LSE-AIM:UTK), a specialty finance company focused on technology transfer, and Bacterin International, Inc., a developer and manufacturer of elutive bioactive coatings for medical devices, are pleased to announce that they have signed a strategic alliance agreement.

"We are enthusiastic about working with UTEK, whose technology transfer model is unique in the industry. This alliance may assist us in locating and acquiring technology and intellectual properties to complement current research and development projects, as well as expanding our core competencies," commented Guy Cook, Chief Executive Officer of Bacterin International, Inc. "Accordingly, we expect Bacterin's product line of coated medical devices to broaden significantly as a result of working with UTEK."

"UTEK looks forward to working with Bacterin International, Inc. to identify potential technology acquisition opportunities that fit its strategic vision," commented William Porter, Chief Technology Transfer Officer of UTEK Corporation.

Through its strategic alliance agreements, UTEK assists companies in enhancing their new product pipeline with the acquisition of proprietary intellectual capital from universities and laboratory research centers. Strategic alliance agreements are generally cancelable by either party with thirty days advance written notice.

About Bacterin International, Inc.

Bacterin International develops novel anti-infective coatings based on proprietary knowledge of the physiological changes made by microbes as they sense and adapt to changes in their environment. Bacterin manufactures and licenses bioactive coatings for medical applications. As an early-stage, rapidly growing company, our current priorities are biofilm inhibition, drug delivery and anti-thrombotic factors for medical device coatings. For more information about Bacterin International, Inc., please visit its website at http://www.bacterin.com.

About UTEK Corporation

UTEK(R) is a specialty finance company focused on technology transfer. UTEK's services enable companies to acquire innovative technologies from universities and research laboratories worldwide. UTEK facilitates the identification and acquisition of external technologies for clients in exchange for their equity securities. This unique process is called U2B(R). In addition, UTEK offers companies the tools to search, analyze and manage university intellectual properties. UTEK is a business development company with operations in the United States, United Kingdom and Israel. For more information about UTEK, please visit its website at http://www.utekcorp.com.

Forward-Looking Statements 

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as UTEK or Bacterin International, Inc. "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe UTEK's or Bacterin International, Inc.'s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of UTEK or Bacterin International, Inc., as appropriate, and the valuation of UTEK's investment portfolio, which could cause actual results to differ materially from those currently anticipated. Although UTEK and Bacterin International, Inc. believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and both UTEK and Bacterin International, Inc. do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

UTEK's operating results could fluctuate significantly due to a number of factors. These factors include the small number of transactions that are completed each quarter, the value of individual transactions, the timing of the recognition and the magnitude of unrealized gains and losses, UTEK's dependence on the performance of companies in its portfolio, the possibility that advances in technology could render the technologies it has transferred obsolete, the loss of technology licenses by companies in its portfolio, the degree to which it encounters competition in its markets, the volatility of the stock market and the volatility of the valuations of the companies it has invested in as it relates to its realized and unrealized gains and losses, the concentration of investments in a small number of companies, as well as other general economic conditions. As a result of these and other factors, current results may not be indicative of UTEK's future performance. For more information on UTEK and for a more complete discussion of the risks pertaining to an investment in UTEK, please refer to UTEK's filings with the Securities and Exchange Commission.